In our study, EA stimulation at acupoints GV20 and ST36 was shown to serve as a therapeutic strategy for the attenuation of neurofunction deficits, reductions in the cerebral infarction area, and enhancement of the protein and mRNA expression of EPO, the EpoR, p-JAK2, JAK2, p-STAT3, and STAT3 in the model of CIRI. This evidence concerns the gene EPO and cerebral infarction.